2011

September - TechGrowth Ohio and Southern Ohio Creates Companies (SOCC) have made a pre-seed investment in Promiliad to help develop DHFR inhibitors as a treatment for antibiotic resistant infections.

July - Promiliad has executed an exclusive license with the University of Connecticut to develop a novel class of dihydrofolate reductase (DHFR) inhibitors as broad spectrum antibacterial agents.


2009

October - Promiliad has been awarded a Phase II STTR grant from the National Institutes of Health to develop novel antifolates as therapeutics for the treatment of MRSA.

August Promiliad has been awarded a Phase I SBIR grant from the National Institutes of Health. The goal of this project is to discover new antibiotics based on the inhibition of fatty acid biosynthesis in pathogenic bacteria.


2008

September - Promiliad has been awarded a Phase I SBIR grant from the National Institutes of Health. This project is aimed at the identification of a new structural class of isoindolinone antibacterial agents.

July - Promiliad has been awarded a Phase I STTR from the National Institutes of Health. This new project seeks to identify potent and selective dihydrofolate reductase (DHFR) inhibitors for treating Cryptosporidiosis.

January - We are pleased to announce a significant upgrade to our nonactin production capabilities. Nonactin is a naturally prodced ionophore that is used in ammonium selective electrodes; it formed in fermentations of Streptomyces griseus. Through genetic manipulation of the producing strain we have greatly improved the fermentation yield of nonactin. As of January 1, 2008, we will consolidate our offerings of nonactin to just one grade, NONACTIN SELECT , a product with a unique combination of price and purity.


2007

May - Researchers at Promiliad Biopharma announce the development of a new class of antibiotic with significant activity against Bacillus anthracis. The triazoloamides are a hybrid of a natural and synthetic structures developed using Promiliad Biopharma's ReBACS technology. As few new classes of antibiotic have been discovered in the last 25 years, the discovery of a new lead with broad activity against Gram positive pathogens, and Bacillus anthracis in particular, is quite exciting. The next stage in the development of these compounds will be a pre-clinical testing to show efficacy in bacterial infection models.

2006

August - Promiliad Biopharma was awarded a Phase I STTR award to develop new inhibitors of dihydrofolate reductase as potential agents with selectivity against Cryptosporidium.

May - Promiliad Biopharma was awarded a Phase II STTR grant from the National Institutes of Health to continue our development of natural product-like libraries of new chemical entities. This award will allow us to expand our compound collection to a size needed for commercialization.

2005

July - Promiliad Biopharma was awarded a Phase I STTR grant from the National Institutes of Health to study methods to introduce chemical diversity into the sugar moieties of macrolide antibiotics.

June - Promiliad Biopharma was awarded a Phase 0 SBIR award from the Montana Department of Commerce to develop natural product-like combinatorial libraries.

June - Promiliad Biopharma was awarded a Phase 1.5 SBIR award from the Montana Department of Commerce.

2004

August - Promiliad Biopharma was awarded a Phase I STTR grant from the National Institutes of Health (NIGMS) for the development of new macrolide antibiotic scaffolds and combinatorial libraries based upon recombinant natural products.

2003

December - Nigel Priestley, CEO, gave a Plenary presentation entitled "ReBACS: Recombinant Biotechnology Assisted Combinatorial Synthesis" at the 13th International Symposium on the Biology of Actinomycetes in Melbourne, Australia.